-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
Form SCHEDULE 13G/A CRISPR Therapeutics AG Filed by: ARK Investment Management LLC
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Lowered to $44 at Baird
-
-
-
-
-
-
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Raised to $80 at H.C. Wainwright
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on CRISPR Therapeutics (CRSP)
-
456,518 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

